Re­mod­el­ing REMS: FDA kicks off guid­ance se­ries with draft on new frame­work

In the first of what’s ex­pect­ed to be a se­ries of REMS-re­lat­ed ad­vice for the in­dus­try, the FDA on Mon­day un­veiled new draft guid­ance on how to im­prove the safe­ty pro­grams of­ten at­tached to high­er-risk drugs.

The 26-page draft lays out the FDA’s think­ing to help spon­sors de­sign, im­ple­ment and eval­u­ate a risk eval­u­a­tion and mit­i­ga­tion strat­e­gy, or REMS. The pro­grams can, for ex­am­ple, re­quire drug­mak­ers to de­vel­op com­mu­ni­ca­tion plans with pa­tients and doc­tors, or take oth­er steps to re­duce po­ten­tial safe­ty is­sues.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.